11:30 AM EDT, 05/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our target price from $11 to $7.50, 3.4x our 2025 EPS forecast, a discount to peers due to lower growth. We lift our 2025 EPS forecast by $0.02 to $2.21 and lower 2026's by $0.29 to $2.42. Q1 EPS of $0.50 vs. $0.67, was $0.01 above consensus. First quarter results were challenging - revenues fell 11% Y/Y to $3,254.3M, primarily due to the negative impact from its Indore facility issues. This decline was partially offset by growth in certain complex products in N. America and strong performance in Europe. VTRS took a goodwill impairment charge of $2.9B, reflecting increased uncertainty and volatility in the operating environment. VTRS's ability to generate $67M in new product revenues during Q1 and its expectation to deliver $450M-$550M for the full year suggests ongoing innovation efforts. However, the significant impact of the Indore facility issues on generics sales highlights the operational risks facing the company. We also see pharmaceutical tariffs as a future risk, contributing to our revised opinion on the shares.